Výsledky vyhledávání

Akademický článek

Adriforant is a functional antagonist of histamine receptor 4 and attenuates itch and skin inflammation in mice.

Autor: Uluckan Ö; Novartis Institutes for BioMedical Research, Autoimmunity, Transplantation and Inflammation; Novartis Pharma AG, CH-4056, Basel, Switzerland., Bruno S; Novartis Institutes for BioMedical Research, Autoimmunity, Transplantation and Inflammation; Novartis Pharma AG, CH-4056, Basel, Switzerland., Wang Y; Novartis Institutes for BioMedical Research, Autoimmunity, Transplantation and Inflammation; Novartis Pharma AG, CH-4056, Basel, Switzerland., Wack N; Novartis Institutes for BioMedical Research, Autoimmunity, Transplantation and Inflammation; Novartis Pharma AG, CH-4056, Basel, Switzerland., Wilzopolski J; Institut für Pharmakologie und Toxikologie, Veterinärmedizin, Freie Universität Berlin, Koserstraße 20, 14195, Berlin, Germany; Bundesinstitut für Risikobewertung, Experimentelle Toxikologie und ZEBET, Diedersdorfer Weg 1, 12277, Berlin, Germany., Goetschy JF; Novartis Institutes for BioMedical Research, Autoimmunity, Transplantation and Inflammation; Novartis Pharma AG, CH-4056, Basel, Switzerland., Delucis-Bronn C; Novartis Institutes for BioMedical Research, Autoimmunity, Transplantation and Inflammation; Novartis Pharma AG, CH-4056, Basel, Switzerland., Urban B; Novartis Institutes for BioMedical Research, Autoimmunity, Transplantation and Inflammation; Novartis Pharma AG, CH-4056, Basel, Switzerland., Fehlmann D; Novartis Institutes for BioMedical Research, Autoimmunity, Transplantation and Inflammation; Novartis Pharma AG, CH-4056, Basel, Switzerland., Stark H; Heinrich Heine University Düsseldorf, Institute of Pharmaceutical and Medicinal Chemistry, Universitätsstr. 1, 40225, Düsseldorf, Germany., Hauchard A; Novartis Institutes for BioMedical Research, Autoimmunity, Transplantation and Inflammation; Novartis Pharma AG, CH-4056, Basel, Switzerland., Roussel E; Novartis Institutes for BioMedical Research, Autoimmunity, Transplantation and Inflammation; Novartis Pharma AG, CH-4056, Basel, Switzerland., Kempf D; Novartis Institutes for BioMedical Research, Autoimmunity, Transplantation and Inflammation; Novartis Pharma AG, CH-4056, Basel, Switzerland., Kaupmann K; Novartis Institutes for BioMedical Research, Autoimmunity, Transplantation and Inflammation; Novartis Pharma AG, CH-4056, Basel, Switzerland., Raulf F; Novartis Institutes for BioMedical Research, Autoimmunity, Transplantation and Inflammation; Novartis Pharma AG, CH-4056, Basel, Switzerland., Bäumer W; Institut für Pharmakologie und Toxikologie, Veterinärmedizin, Freie Universität Berlin, Koserstraße 20, 14195, Berlin, Germany., Röhn TA; Novartis Institutes for BioMedical Research, Autoimmunity, Transplantation and Inflammation; Novartis Pharma AG, CH-4056, Basel, Switzerland., Zerwes HG; Novartis Institutes for BioMedical Research, Autoimmunity, Transplantation and Inflammation; Novartis Pharma AG, CH-4056, Basel, Switzerland. Electronic address: hans-guenter.zerwes_ext@novartis.com.

Publikováno v: European journal of pharmacology [Eur J Pharmacol] 2023 Apr 15; Vol. 945, pp. 175533. Date of Electronic Publication: 2023 Jan 21.

Zobrazit plný text záznamu

Akademický článek

Disease Association of Anti‒Carboxyethyl Lysine Autoantibodies in Hidradenitis Suppurativa.

Autor: Macchiarella G; Biomarker Development (BMD), Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland; Biozentrum, Faculty of Sciences, University of Basel, Basel, Switzerland., Cornacchione V; NIBR Biologics Center (NBC), Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Cojean C; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Riker J; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Wang Y; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Te H; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Ceci M; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Gudjonsson JE; Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA., Gaulis S; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Goetschy JF; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Wollschlegel A; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Gass SK; Department of Plastic, Reconstructive & Aesthetic Surgery and Hand Surgery, University Hospital, University of Basel, Switzerland., Oetliker-Contin S; Department of Plastic, Reconstructive & Aesthetic Surgery and Hand Surgery, University Hospital, University of Basel, Switzerland., Wettstein-Ling B; Department of Plastic, Reconstructive & Aesthetic Surgery and Hand Surgery, University Hospital, University of Basel, Switzerland., Schaefer DJ; Department of Plastic, Reconstructive & Aesthetic Surgery and Hand Surgery, University Hospital, University of Basel, Switzerland., Meschberger P; Department of Surgery, Kantonsspital Baselland, Liestal, Switzerland., de Roche R; Praxis beim Merian Iselin, Basel, Switzerland., Osinga R; Department of Plastic, Reconstructive & Aesthetic Surgery and Hand Surgery, University Hospital, University of Basel, Switzerland; Praxis beim Merian Iselin, Basel, Switzerland., Wieczorek G; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Naumann U; Chemical Biology and Therapeutics (CBT), Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Lehmann JCU; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Schubart A; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Hofmann A; Biotherapeutic and Analytical Technologies, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Roth L; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Florencia EF; Department of Dermatology, Erasmus University Medical Centre, Rotterdam, the Netherlands., Loesche C; Translational Medicine, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Traggiai E; NIBR Biologics Center (NBC), Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Avrameas A; Biomarker Development (BMD), Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Prens EP; Department of Dermatology, Erasmus University Medical Centre, Rotterdam, the Netherlands., Röhn TA; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Roediger B; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland. Electronic address: ben.roediger@novartis.com.

Publikováno v: The Journal of investigative dermatology [J Invest Dermatol] 2023 Feb; Vol. 143 (2), pp. 273-283.e12. Date of Electronic Publication: 2022 Sep 16.

Zobrazit plný text záznamu

Editorial & Opinion

A CARD10-Dependent Tonic Signalosome Activates MALT1 Paracaspase and Regulates IL-17/TNF-α-Driven Keratinocyte Inflammation.

Autor: Israël L; Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland., Bardet M; Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland., Huppertz A; Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland., Mercado N; Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland., Ginster S; Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland., Unterreiner A; Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland., Schlierf A; Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland., Goetschy JF; Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland., Zerwes HG; Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland., Roth L; Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland., Kolbinger F; Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland., Bornancin F; Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland. Electronic address: frederic.bornancin@novartis.com.

Publikováno v: The Journal of investigative dermatology [J Invest Dermatol] 2018 Sep; Vol. 138 (9), pp. 2075-2079. Date of Electronic Publication: 2018 Mar 20.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání